Jazz Pharmaceuticals Reports Record Q3 Revenue and Provides 2026 Guidance
Jazz Pharmaceuticals (JAZZ) reported record third-quarter revenues of $1.24 billion, representing a 10% increase year-over-year. CEO Renée Galá highlighted the company's progress in diversifying its portfolio and driving innovation to support long-term growth. The company provided optimistic forward-looking guidance, projecting 2026 revenues between $4.775 billion and $4.85 billion. A key driver for this growth is the anticipated launch of Ziihera, which management estimates could reach peak sales potential of $3 billion to $5 billion.
Tickers: $JAZZ
Topics: earnings report quarterly results revenue growth
Read the full article at Seeking Alpha
Part of the story Palantir Technologies Shares Decline Despite Record Q3 Revenue and Raised Guidance (16 articles)